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Autoimmune and thyroid conditions account for a substantial proportion of the morbidity 
and mortality experienced in the United States, affecting >40 million Americans combined. Co-
occurrence of both an autoimmune and thyroid condition is also likely, particularly among 
women. Epidemiologic studies on both sets of conditions have examined many risk factors, 
including demographic, lifestyle, genetic, and environmental risk factors. However, one area 
which has been neglected is the effect of early life exposures on the development of autoimmune 
and thyroid conditions. To investigate the potential association between an individual’s birth 
weight (by category; <6lbs, 6-7lbs 15 oz, 8-9 lbs 15oz, ≥10lbs) and risk for autoimmune and 
thyroid conditions, we performed a nested case-control study among 76,087 multiethnic 
postpartum women in the Women’s Health Initiative (WHI) Observational cohort. Logistic 
regression models were used to estimate crude and adjusted odds ratios for associations between 
birth weight and: (1) autoimmune conditions (rheumatoid arthritis (RA), systemic lupus 
erythematosus (lupus), multiple sclerosis, type 1 diabetes, and ulcerative colitis/Crohn’s disease), 
and (2) thyroid conditions (hypothyroidism, hyperthyroidism, and goiter). After adjustments, 
birth weight was positively associated with odds for any thyroid condition (combined; P<0.02) 
and negatively associated with odds for hyperthyroidism (P=0.0002) within our prevalent model. 
Further, birth weight was significantly associated with hypothyroidism (P=0.0009) such that 
women weighing <6 lbs, 8-9.9 lbs, or ≥10lbs were at increased odds for hypothyroidism. No 
significant associations were observed between birth weight and any of the autoimmune 
conditions or goiter.  Lupus (HR 1.51 [1.12, 2.03]) in all models and Hypothyroidism with the 
unadjusted model (HR 1.18 [1.05,1.31] were also demonstrated to be at increased risk within the 
incident analysis.  RA and Hypothyroidism produced no significant results within the Incident 
analysis. Our results further support the Developmental Origins of Health and Disease Hypothesis 
postulating that diseases that occur in childhood and later in life result from environmental 
exposures in utero and early childhood, extending the hypothesis to include thyroid conditions. 
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Autoimmune conditions pose a significant health risk around the world. It is 
estimated that there are 14.7 million people living with an autoimmune condition in the 
US1. The prevalence of autoimmune disease is on the rise from 9 million people in 19972 
to 14.7 million people in 20121. Common autoimmune conditions include type 1 diabetes 
(T1D), systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatic arthritis 
(RA), ulcerative colitis (UC), and Crohn’s disease (CD). 
Thyroid conditions have a burden similar in scale to autoimmune conditions. 
Currently there are an estimated 20 million Americans living with a thyroid condition. 
Thyroid conditions are classified into 4 main categories: underactive thyroid 
(hypothyroidism), overactive thyroid (hyperthyroidism), goiter, and thyroid nodules. The 
most common causes of thyroid conditions are cancers, autoimmune thyroid diseases 
(AITDs) such as Hashimoto’s thyroiditis and Graves’ disease, and iodine deficiencies. 
While not all thyroid conditions are autoimmune in nature, a bulk of autoimmune thyroid 
conditions are underdiagnosed as it is often easier to just manage the symptoms then 
diagnose the condition3,4.  
Co-occurrence of both an autoimmune and thyroid condition is also likely, 
particularly among women5–7. It is estimated that 5-10% of RA patients and 17-30% of 
T1D patients will suffer from some sort of thyroid condition 8,9. Further, thyroid, and 
autoimmune conditions share many common risk factors, including smoking, body mass 
index (BMI), age, ethnicity, and presence of an immune condition. By in large, however 
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,the most consistent and major risk factors for autoimmune and thyroid conditions are 
family history and sex5,10–12: Women bear most of the burden of both autoimmune and 
thyroid disease.  
1.2 Epidemiology: Autoimmune Conditions 
The immune system controls the body’s ability to eradicate and control infections 
from other pathogenic organisms, as well as assist in the repair process of other organ 
systems. The immune system functions through a variety of cell types and proteins that 
are made to recognize foreign invaders. Autoimmune conditions can result from the mis 
regulation and/or mistargeting of the immune system which results in immune system 
recognizing the body as a foreign invader13. As a group, each of the conditions are 
classified by autoantibody activity, or the presence of immune receptors that target one’s 
own body 13–15. These autoantibodies can affect different parts of the body, such as the 
pancreas (T1D) 16, joints (RA) 17, neurons (MS) 18, gastrointestinal system (UC/CD) 19, or 
just general cell surface receptors that are ubiquitous throughout the body (lupus) 20. 
While some autoimmune conditions, such as T1D, have very clear clinical presentation 
many others manifest with non-descript symptoms4. For example, RA shares a lot of 
similar clinical symptoms with Osteoarthritis often leading to the underdiagnoses of 
Rheumatoid arthritis.  
1.2.1 Lupus 
Lupus is an autoimmune condition which targets a wide variety of body systems 
causing widespread inflammation and tissue damage in the joints, skin, lungs, kidneys, 
blood vessels, and brain 21–24. According to the Lupus Foundation of America, 1.5 million 
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Americans are estimated to be living with some form of lupus, 23 90% of which are 
women. Individuals are typically diagnosed with SLE between the ages of 15-44 and 
experience a variety of symptoms, such as skin rashes, fevers, joint pain/swelling, and 
fatigue 23.  Persons afflicted with lupus are known to experience periods of “flare ups”, 
during which the individual may experience more severe symptoms or new symptoms 
that they may not have previously had 20,21,25. Flare ups can happen at any time, but are 
especially likely when a person with lupus is experiencing higher levels of emotional, 
mental, or physical stress 20.   
Lupus can be deadly if left untreated. Early death as a result lupus is usually due 
to complications caused by infections, while death later in life is typically associated with 
atherosclerosis, or the buildup of fats on large to medium sized arterial walls 26. The 
increased risk for atherosclerosis in lupus patients has been demonstrated to be associated 
with high disease activity, treatments for the disease and other markers such as 
antiphospholipid antibodies27. Treatments for lupus focus on managing symptoms and 
can vary widely based on the individual 20. Common treatments can include non-steroidal 
anti-inflammatory drugs (NSAIDs), antimalarials, corticosteroids, immunosuppressants, 
and monoclonal antibodies. 
There are several known risk factors for the development of lupus. The most 
prevalent risk factor is sex: women are six times more likely to develop lupus than men 
28. Additional prominent risk factors include minority racial and ethnic groups, age (15-
44 years), and family history 28. Further, genome-wide association studies (GWAS) have 




1.2.2 Multiple Sclerosis 
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system 
30–32. MS is characterized by an exaggerated immune response to myelin, the compound 
that coats and insulates the neuron fibers 30, resulting in communication problems 
between the brain and the rest of the body. Advanced stages of MS can even lead to 
permanent nerve damage, such as degradation of the axon itself 30,31. It is estimated that 
2.3 million people, globally, are living with MS. Diagnoses usually occur between 20-50 
years of age with women bearing most of the burden of disease. Common symptoms of 
MS include: fatigue, vision problems, numbness, muscle spasm, mobility problems, and 
cognitive issues with thinking and mental health. 30,31.  
MS is a progressive disease meaning it will continue to worsen over the course of 
the person’s life 18,33.. Relapses, pr periods of intense symptoms, usually occur rapidly, 
reaching a plateau that can last weeks until they subside 18,33. Relapsing-remitting MS 
(RRMS) is the least severe and causes the least amount of complications. Within 15 years 
of the initial diagnosis, RRMS can develop into secondary progressive MS (SPMS), 
which is more severe. SPMS is characterized by its neurodegenerative complications: 
cognitive impairment and increasing severity of common MS symptoms 18,33. The final 
form of MS is primary progressive MS (PPMS), which is characterized by a faster 
progression, more localized disease etiology, and more severe complications/symptoms, 
such as paraparesis and cognitive and progressive visual failure 33. While treatments for 
MS are broad and specific to the individual 18,30,33, there are two major strategies used: 
disease modifying treatments that reconstitute or suppress the immune system, and 
symptom-managing treatments 18. 
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Risk factors for MS are similar to those of other autoimmune conditions 2,31.  Age, 
female sex, geographical region, and racial or ethnic background are the most well-
known and well-established risk factors 32. Specifically, women bear most of the burden 
of disease (74% of cases) 31, and individuals of northern European-ancestry are diagnosed 
more frequently than those of other ancestries. There is also a positive association 
between MS and distance from the equator where those who live further from the equator 
have a higher risk for disease 18,30. Over 230 genetic variants have also demonstrated 
significant association with the risk for MS 34. 
1.2.3 Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) is a common autoimmune condition characterized by 
inflammation of the lining of the joints that can eventually result in bone erosion and/or 
joint deformity 35–37. In some individuals, RA can also damage the skin, eyes, lungs, 
heart, and blood vessels. RA is one of the most characterized autoimmune conditions, 
estimated to afflict 1.36 million people in the US with diagnoses starting as early as 30 
years of age.  
RA causes a variety of symptoms including tender or swollen joints, stiffness, 
fatigue, fever, and even loss of appetite 36. As mentioned above, RA does not have to 
affect only the joints but has been shown to cause complications with other body systems. 
These complications can range from minor effects such as mouth dryness to more serious 
inflammation of the cardiovascular system35–37. The hallmark treatment for rheumatoid 
arthritis is the use of disease modifying antirheumatic drugs (DMARDs). Drugs included 
in the treatment of RA include: hydroxychloroquine, methotrexate, sulfasalazine, 
leflunomide, minocycline, azathioprine, cyclosporine, gold, cyclophosphamide, 
 
 6 
antirheumatic biologic agents (i.e., tumor necrosis factor-α and interleukin 1 antagonists) 
17,38–40
.  
Because RA is one of the more common autoimmune conditions 17,36,41, quite a bit 
is known about its epidemiology. Common risk factors for RA include age, smoking, 
higher BMI, and family history/genetic predisposition 37. There is also a large sex 
disparity: 75% of individuals diagnosed with RA are women 41. However, both fish and 
moderate alcohol consumption have been demonstrated to protect against RA 
development and symptom expression 37. 
1.2.4 Type 1 Diabetes 
Type 1 diabetes (T1D) is a chronic autoimmune condition in which the pancreas 
produces little to no insulin as a result of destruction or dysfunction of pancreatic beta 
cells 42,43. T1D has a global incidence of about 15 per 100,000 people. Within the US, the 
incidence is higher at 20 per 100,000 persons with a prevalence of 12.2 per 100,000 
people. Unlike other autoimmune conditions, there is no difference in disease prevalence 
between sexes 43,44; however, there is a significant difference in mortality 45 with women 
being at a 40% greater risk of death.  
There are several broad, moderate symptoms associated with T1D, ranging from 
frequent urination to extreme fatigue 46,47. However, there are several severe and/or life-
threatening complications that can arise from mistreatment or lack of treatment, including 
diabetic ketoacidosis, neuropathy, glaucoma, cataracts, and various cardiovascular 
diseases such as high blood pressure and strokes 46,47. The most unique complication is 
diabetic ketoacidosis, which occurs when blood sugar levels are high, and ketones begin 
to build up within the blood stream. The primary treatment for T1D is insulin injection 47. 
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The other treatments include lifestyle changes, such as diet, blood sugar monitoring, and 
physical activity. 
With the exact cause of T1D unknown, little is also known about the risk factors 
for T1D. Individuals with a family history of T1D are an increased risk for developing 
the disease; in fact, genetic studies have identified 80 loci associated with T1D48, further 
illustrating the genetic nature of the condition. Other suggested risk factors for T1D 
include: white race 43,49; adolescent age 49, puberty; and environmental stressors such as 
entero-infections during pregnancy, Vitamin D deficiency, and intestinal microbiota50. 
Unlike type 2 diabetes, diet and lifestyle habits are not associated with risk for T1D. 
1.2.5 Ulcerative colitis/ Crohn’s disease 
Ulcerative colitis (UC) and Crohn’s disease (CD) are autoimmune conditions of 
the gastrointestinal tract 19,51–53. While the two conditions are very similar in presentation 
and epidemiology, UC is continuous inflammation of the inner most layer of the colon 
whereas CD can occur anywhere along the digestive tract (from mouth to anus) with both 
inflamed and healthy tissues mixed together 19,51. Around 214 people out of 100,000 
persons per year in the United states will be diagnosed with UC with CD being more rare 
at 3.1-20.2 per 100,000 individuals per year51,53. Unlike many of the other autoimmune 
conditions previously mentioned, there is no sex discrepancy in prevalence rates of UC or 
CD 51,53. 
Symptoms of both UC and CD include persistent and often bloody diarrhea, 
abdominal cramps/pain, and bowel urgency 19. While the conditions are limited to the 
gastrointestinal tract, complications of both conditions can affect a person’s overall health 
such as fevers, weight loss, low energy/fatigue, loss of appetite, anemia, and delayed 
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growth or development in children 51. There are many different treatments for UC/CD. 
According to The Chron’s and Colitis foundation, there are 30 FDA approved drugs 
across 5 classes 54,55. The medications as well as dietary changes are the main treatments 
for UC/CD. In some instances, an individual may undergo surgery to remove a heavily 
affected portion of the bowel, and the remaining ends are joined together 53.  
The exact causes of UC and CD are unknown; however, both are much more 
common in individuals with a family history of either condition. Previously, diet and 
stress were suspected risk factors; research has now shown these factors may aggravate 
the condition and cause flare-ups but are not responsible for disease etiology 19,52. It is 
now believed that UC and CD are triggered by a malfunction in the immune system of 
those with a genetic susceptibility or predisposition for UC/CD 19. It has been suggested 
that an abnormal immune response to an invading virus or bacterium my cause the 
immune system to attack cells in the digestive tract as well, leading to UC/CD. In fact, 
there is a known association with the presence of Clostridium difficile and flare ups of 
both UC and CD. Nonetheless, the cause of the malfunctioning immune system or 
abnormal immune response is still to be determined 51,52.   
1.3 Epidemiology: Thyroid Conditions 
The thyroid is a small, butterfly-shaped endocrine gland that sits along the front of 
the windpipe. It has two lobes that are connected by the isthmus in the middle56,57. The 
thyroid is primarily responsible for secreting two thyroid hormones—triiodothyronine 
(T3) and thyroxine (T4)—and a peptide hormone called calcitonin. T3 and T4 are 
responsible for maintaining the metabolic rate, cardiovascular function, sexual function, 
sleep patterns, and protein synthesis, as well as growth and development in children56,57. 
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Calcitonin plays a role in calcium homeostasis. Thyroid hormone production in the 
thyroid is regulated by thyroid-stimulating hormone (TSH) released by the anterior 
pituitary gland. Clinically significant conditions of the thyroid include functional 
disorders58,59 (hyper- and hypothyroidism), as well as several diseases (e.g., nodules60, 
goiter61, Graves’ disease62, Hashimoto’s thyroiditis63, thyroid cancer64). While not all 
thyroid conditions are autoimmune diseases, many have autoimmune etiologies. One of 
the leading causes of hyper- and hypothyroidism is Graves’ Disease and Hashimoto’s 
thyroiditis, respectively 6,58,65, both of which are autoimmune conditions. Goiter 
etiologies also include Graves’ disease and Hashimoto’s thyroiditis 3.  
1.3.1 Hyperthyroidism 
Overactive thyroid, or hyperthyroidism, occurs when the thyroid gland produces 
too much T4, resulting in unintentional weight loss from an accelerated metabolism and a 
rapid and/or irregular heartbeat 58,62,66. In the US it is estimated that 1-3% of the 
population is living with overt hyperthyroidism 67. It can be caused by a number of 
conditions, including thyroiditis, thyroid nodules and Graves’ disease 62,68. Other 
symptoms of hyperthyroidism include: heart palpitations, fatigue, tremors, anxiety, heat 
intolerance, and disturbed sleep 58. Treatment for hyperthyroidism is highly dependent on 
the cause of hyperthyroidism 69–72. Medication against thyroid hormone production, 
radioactive iodine, and surgery are among the most common treatments for 
hyperthyroidism.  
There are several known risk factors for hyperthyroidism. Women are affected 
more frequently than men 58,65. with an average onset between 40-60 years of age 58,65. 
Individuals are also at higher risk if they are of white race or of Japanese ancestry, 
 
 10 
consume a diet high in saltwater fish and/or iodine, have an autoimmune condition, or 
have a family history of hyperthyroidism or Graves’ disease 58,69,73.  
1.3.2 Hypothyroidism 
An underactive thyroid, or hypothyroidism, is a condition in which the thyroid 
gland does not produce enough thyroid hormone 59. Hypothyroidism is among the more 
common conditions of the thyroid in western countries with between 3-7% of the US 
population having the condition 59. Hypothyroidism may be a result of a number of 
factors, including: Hashimoto’s thyroiditis or other autoimmune disease 63,74, over-
response to hyperthyroidism treatment, thyroid surgery, radiation therapy, medications, a 
pituitary disorder, or an iodine deficiency. Cold and dry skin, brittle nails, bradycardia, 
delayed reactions, ataxia, fatigue, and elevated blood pressure are all common symptoms 
of an underactive thyroid 59,63. Untreated hypothyroidism can lead to several health 
problems, such as goiter, heart problems, mental health issues, neuropathies, myxedema, 
infertility, and birth defects 59. The primary treatment for hypothyroidism is 
levothyroxine, a synthetic form of thyroid stimulating hormone (TSH). 
Epidemiological studies of hypothyroidism have identified several common risk 
factors for disease development. Like hyperthyroidism, women are more likely to 
develop hypothyroidism than men. Additional risk factors include: >60 years of age, 
family history of thyroid disease, presence of an autoimmune condition, history of 
treatment with radioactive iodine or anti-thyroid medications, history of radiation to the 
neck or upper chest, thyroid surgery, and having been pregnant or delivered a baby within 




Goiter, or the enlargement of the thyroid, can be broken up into two main groups: 
diffuse and nodular goiter. While iodine deficiency is the most common cause of goiter 
worldwide 3, chronic autoimmune diseases, such as Hashimto’s thyroiditis and Graves’ 
disease are the most common causes of goiter within the US 60,61. In the US it is estimated 
that 4.7% of the population is living with some form of goiter61.  
The symptoms of goiter can vary due to the different types and causes of the 
goiter. Goiters come in two forms toxic and non-toxic 3,60,71. Toxic goiter is characterized 
by increasing size of the thyroid partnered with the over production of the thyroid 
hormone thyroxine. Toxic goiter shares similar symptomology with hyperthyroidism, 
and, if left unchecked, can result in additional physical symptoms such as airway 
obstruction due to the large size of thyroid. Treatment options for toxic goiter typically 
include radioiodine therapy, antithyroid medication, and/or surgery71. Non-toxic goiter 
are only characterized by increasing thyroid size but is not accompanied by 
hyperthyroidism 60. Non-toxic goiter can also be treated with radioiodine therapy, 
antithyroid medication, and/or surgery71 unless it is accompanied by hypothyroidism, in 
which case levothyroxine can be used in place of antithyroid medication 60. 
 Because goiters have multiple etiologies, complications vary based on the cause 
of the disease 60,713,63,72. However, there is on complication that is ubiquitous across goiter 
types: increased risk for thyroid cancer. Studies have shown that 10-20% of persons with 
a goiter will develop thyroid cancer 75. Further, if the goiter is allowed to grow in size, 
upper airway obstructions may become problematic and require surgical removal of the 
goiter.   
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Goiter does not have many independent risk factors. The most well researched 
risk factors for developing goiter are iodine deficiency61, and autoimmune conditions, 
such as Hashimoto’s thyroiditis or Graves Disease3,76.  
1.4 Birthweight and the risk for autoimmune and thyroid conditions 
The Developmental Origins of Health and Disease Hypothesis (DOHD), (also 
known as the “fetal origins hypothesis” or the “Barker Hypothesis”) is a hypothesis that 
postulates that chronic disorders or conditions in later life can result from environmental 
factors in utero (e.g., fetal malnutrition) and early childhood that permanently “program” 
the structure and function of systems within the body 77. The hypothesis, outlined by 
David Barker in “Fetal and Infant Origins of Adult Disease” (1992) 78 has demonstrated 
an individual’s birth weight as a risk factor for many chronic diseases in both children 
and adults, such as autism79, attention deficit/hyperactivity disorder80, cardiovascular 
disease 81, type 2 diabetes82, cancer83, and later-life disability 84.   
There is also evidence that prenatal factors, such as an individual’s birth weight, 
may influence the development of the immune system. Children born at low and high 
birth weights are at substantially increased risk for asthma85. Further, children born at 
higher birth weights are at increased risk for allergic diseases, including eczema, food 
allergies, hay fever, and anaphylaxis86. Although alterations of the immune system can 
persist into adulthood, the relationship of the DOHD and immune conditions remains 
elusive for select conditions. There are several conditions with limited or conflicting 
evidence while others like T1D are thoroughly examined. 
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1.5 Physiological Connection 
Fetal insults in utero, including maternal and fetal exposures that result in infants 
born at both low (<2500 g) and high (≥ 4500 g) birth weights, have been shown to illicit 
epigenetic modifications of genes throughout the genome87. These epigenetic 
mechanisms, which orchestrate fetal growth and development, may also remain 
“programmed” throughout an individual’s life, putting them at risk for later health 
consequences. In fact, several studies have demonstrated significant differences in 
patterns of DNA methylation by birth weight that have persisted past infancy88–90. Further 
investigation is warranted to determine which epigenetic modification(s) may be most 
influential to the development of autoimmune and thyroid conditions.   
Apart from epigenetic modifications, there is some evidence that birth weight may 
influence the development of the immune system. Infants born following intrauterine 
growth restriction (IUGR) have been found to have a global downregulation of the 
immune system, often associated with allergic disorders within children 82. Infants born 
IUGR and with low birth weights (<2500 grams) have also demonstrated a transient shift 
in T-cell and cytokine balance, altering systemic inflammatory responses91,92.  
Additionally, low birth weight has been associated with low grade inflammation as well 
as several innate immune cells such as overall leukocytes, basophils, eosinophils and 
even platelets after adjusting for family history 93, and both inflammation and overactive 
immune responses are known to be risk factors for autoimmune conditions.  
1.6 Study Objectives, Significance, and Innovation 
This study proposes to assess the relationship between an individual’s weight at 
birth and risk for autoimmune (RA, MS, T1D, lupus, and UC/CD) and thyroid 
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(hypothyroidism, hyperthyroidism, and goiter) conditions. Specifically, the aims of the 
study are: 
Aim 1: To assess the relationship between birth weight and the risk of 
autoimmune conditions such as rheumatoid arthritis, lupus, multiple sclerosis, ulcerative 
colitis, Crohn’s disease, and type 1 diabetes. 
 Hypothesis 1: We postulate that infants born at lower weights (< 6lbs) will be at 
an increased risk of developing autoimmune conditions overall. 
 Aim 2: To assess the relationship between birth weight and the risk of thyroid 
conditions such as hyperthyroidism, hypothyroidism, and goiter. 
 Hypothesis 2: We postulate that infants born at lower weights (< 6 lbs.) will be at 
an increased risk of developing thyroid conditions overall. 
Because many autoimmune conditions are known to also affect the thyroid, it is 
common for individuals to have at least one autoimmune condition and a thyroid 
condition. This co-occurrence suggests a natural combination of the two sets of 
phenotypes. Studies relating birth weight to autoimmune and thyroid conditions are 
sparse and most have been conflicting. This study would be among the first to look at a 
large range of autoimmune and thyroid conditions within the same population rather than 
examine individual conditions in different populations. Further, the sample size and 









2.1 Women’s Health Initiative 
The Women’s Health Initiative (WHI) is an ongoing prospective cohort study 
designed to study major causes of chronic disease in postmenopausal women. Briefly, 
161,608 post-menopausal women aged 50-79 at enrollment were recruited from the 
general population at 40 US clinical recruitment sites between 1993-1998 94. Participants 
could have enrolled into overlapping clinical trials (WHI-CT; n = 67,932) or the long-
term observational study (WHI-OS; n = 93,676). Detailed information about the WHI’s 
study design, recruitment, and implementation have been described elsewhere 94,95. All 
study protocols were approved by the Institutional Review Board of each participating 
clinical center, and all participants provided written informed consent at study initiation. 
2.2 Baseline Measures 
 Upon entry into the WHI-OS, all women completed structured, self-administered 
questionnaires to collect information on demographics; lifestyle factors; and medical, 
reproductive, and family history. Participants were asked to report their birth weight as 
one of the following categories:  less than 6 pounds (lbs), 6 lbs to 7lbs 15ounces, 8 lbs to 
9lbs 15 oz, and 10 or more lbs. The collection of birth weight is comparable to other 
studies of similar size and has been previously validated within those studies 96. Women 
were also asked to report if they were born 4 or more weeks premature or were part of a 
multiple pregnancy (specifically, a twin or triplet). Further, a physical assessment was 
performed by trained staff to gather accurate measures of weight, height, and waist and 
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hip circumference at baseline. Participants were also asked to bring all current 
medications with them to the physical assessment. 
2.3 Follow-up for outcome ascertainment 
 Clinical outcomes, including incident autoimmune and thyroid condition 
diagnoses, were reported by participants annually through in-person, mailed, and/or 
telephone questionnaires. In the third year of follow-up, women were invited to a follow-
up clinical visit for an updated physical assessment. Like the assessment performed at 
baseline, the follow-up clinical visit was performed to gather updated anthropometric 
measures, as well as an updated list of current medications and other outcome 
information. 
2.4 Outcome definitions and measurement 
Data on prevalent thyroid and autoimmune conditions were obtained at baseline 
through the self-administered questionnaires. Women were first asked to report if a 
doctor had ever told them that they had a thyroid problem (yes/no/don’t know). If they 
answered yes, they were then asked a series of sub-questions (yes/no/don’t know) about 
specific thyroid conditions. We included the following thyroid conditions in our analyses: 
any thyroid gland problem, overactive thyroid, underactive thyroid, and goiter.  
We included the following prevalent autoimmune conditions in our analyses: any 
autoimmune disease, type 1 diabetes (T1D), multiple sclerosis (MS), rheumatoid arthritis 
(RA), lupus (lupus), and Crohn’s disease/ulcerative colitis (CD/UC). We defined 
prevalent MS, lupus, and CD/UC as a self-report of a physician diagnosis of “multiple 
sclerosis”, “systemic erythematosus (‘lupus’ or SLE)”, or “ulcerative colitis or Crohn’s 
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disease”, respectively. Due to the lack of a specific variable for distinguishing those with 
type 1 and type 2 diabetes, we classified women has having T1D if they meet the 
following criteria reported at baseline: 1) self-reported physician diagnosis of ‘sugar 
diabetes when not pregnant; 2) reported the age of diabetes diagnosis < 30; and 3) 
reported using insulin as a treatment for their diabetes. Additionally, as the self-reported 
variable for RA has been poorly validated within WHI and often includes cases of 
osteoarthritis as shown in a previous study 38, we classified women as having prevalent 
RA if they simultaneously met the following criteria:1) self-reported type of arthritis as 
“rheumatoid arthritis” ; and 2) use of disease-modifying antirheumatic drugs (DMARDs).  
Incident data were available for several of the thyroid and autoimmune 
conditions. Beginning in the third year of follow-up, women were asked to self-report 
any new lupus, RA, underactive thyroid, and/or overactive thyroid diagnoses that had 
occurred since the last completed survey. Women were considered as incident cases for 
each outcome if they responded “yes” to a recent diagnosis of lupus, underactive, and/or 
overactive thyroid. Like prevalent RA, women were required to indicate a recent 
diagnosis of RA and use DMARDs to be classified as an incident case of RA. Because 
medication coding only occurred in the third year of follow-up, our incident RA analyses 
were censored at the third year of follow-up. 
2.5 Study Exclusion Criteria 
For our analyses, women were excluded if they reported being born premature 
(n=7,282), reported being a twin or a triplet (n=1,616), or had a missing birth weight 
category (n=11,751). Women who had previously been diagnosed with a particular 
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condition prior to enrollment were excluded from the survival analyses for that same 
condition. 
2.6 Statistical Analyses 
Baseline characteristics of the study participants with and without any 
autoimmune or thyroid condition were examined using t-tests for continuous variables 
and chi-square tests for categorical variables. Logistic regression models were used to 
estimate odds ratios (OR) and their associated 95% confidence intervals (95% CI) 
between a woman’s birth weight and prevalent cases of autoimmune (any, RA, MS, 
lupus, T1D, and UC/CD) or thyroid (any, underactive, overactive, goiter) conditions with 
and without adjusting for potential risk factors.  Cox proportional hazards regression 
models were used to estimate hazard ratios (HR) and 95% CI between a woman’s birth 
weight and incident cases of lupus, RA, underactive thyroid, and overactive thyroid with 
and without adjusting for potential risk factors. For birth weight, we used “6 lbs. to 7 lbs. 
15 oz” as the referent category as infants born full-term within this weight range are 
considered to be of normal birth weight. Covariates selected for inclusion in our models 
are well-known risk factors for most autoimmune and/or thyroid conditions including 
age, race/ethnicity, region, BMI, smoking status, education, Normalized Socio-Economic 
Status (NSES), and alcohol use. All statistical tests were two-sided, and P-values <0.05 
were considered statistically significant. Each outcome was considered independently 
with birth weight; therefore, we did not correct for multiple testing. For conservative 
interpretation, a Bonferroni-adjusted significance threshold of P<0.0035 (0.05/14) could 






Results from the comparison of baseline characteristics are outlined in Table 1. 
Women with any autoimmune condition at baseline were more likely to be younger, 
identify as non-white, have a lower NSES, and have a lower BMI than women who did 
not report the presence of an autoimmune condition at baseline. Conversely, women who 
reported having any thyroid condition at baseline were more likely to be older, identify as 
white, and have a higher BMI, then women who did not report the presence of a thyroid 
condition at baseline.   
Table 2 shows the crude and demographic- and lifestyle-adjusted odds of thyroid 
and autoimmune conditions by category of birth weight. Birth weight was significantly 
and positively associated with odds for any thyroid condition (all types combined) at 
baseline (unadjusted, P<0.0001). The association remained significant after adjustment 
for demographic (P=0.005) and lifestyle (P=0.02) factors, although the strength of the 
association was attenuated. A significant negative association was observed between 
birth weight and the odds for overactive thyroid (adjusted, P=0.009). Further, birth 
weight was significantly associated with underactive thyroid (adjusted, P=0.0002) such 
that women weighing <6 pounds, 8-9.9 pounds or ≥10 pounds at birth were at 
significantly increased odds for underactive thyroid. The magnitude of these associations 
is relatively modest ranging from fully adjusted OR’s of 1.14 (CI 1.02, 1.28) in the No 
significant associations were observed between birth weight and the odds for goiter, RA, 
MS, lupus, T1D, CD/UC, or any autoimmune disease (all types combined). 
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Crude and demographic- and lifestyle-adjusted hazards ratios of incident thyroid 
and autoimmune conditions are presented in Table 3. Women born in the highest birth 
weight category, >10 lbs, were at significantly increased risk for lupus in both crude (HR: 
1.47, 95%CI 1.14-1.94) and adjusted models (demographic-adjusted, HR=1.43, 95% CI 
1.08-1.90; demographic- and lifestyle-adjusted, HR=1.51, 95% CI 1.12-2.03) compared 
to women born weighting between 6 lbs – 7 lbs 15 oz. Women born weighing >10 lbs 
were also at significantly increased risk for underactive thyroid compared to women 
weighing 6 lbs – 7 lbs 15 oz at birth (unadjusted, HR=1.18, 95% CI 1.05-1.31); however, 
this association was attenuated after adjustments for covariates. No significant 
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 In the WHI, a well-established cohort of post-menopausal women, we found that 
women born within the heaviest birth weight category (>10 lbs) were at increased odds 
for underactive thyroid and decreased odds for overactive thyroid compared to women 
born at a normal birth weight. Further, the highest birth weight category was associated 
with increased risk for incident lupus compared to the normal birth weight category.  
4.1 Comparison with prior literature 
 To our knowledge, the body of existing literature for the associations between 
birth weight and most autoimmune conditions is limited and inconsistent. Four studies 
were identified that examined the association between birth weight and RA, of which one 
found no association97, one found individuals born with low birth weights to be at 
decreased odds for RA 98, and three studies found those born at higher birth weights to be 
at increased risk for RA 96,99,100. The study design most comparable to ours was 
performed within the Nurses’ Health Study (NHS)96, a large nationwide prospective 
study. The analysis found an increased risk of RA at the highest birth weight category of 
>4.54 kg (RR 2.1 95% CI 1.2-3.6) compared to the normal birth weight category of 3.2-
3.85 kg. While we found no association in our study between birth weight and RA, the 
NHS included a more thorough ascertainment of the RA outcome with medical chart 
abstraction conducted by trained rheumatologists 96. Even after validation with drug data, 
the RA variable used in the WHI study only reaches an estimated positive predictive 
value of 62.2% 38. 
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We also identified four studies that previously examined the association between 
birth weight and lupus 101–104. Two studies found no association between birth weight and 
lupus when examining birth weight by category 102 or as a continuous variable 101. One 
study performed within the national cohort, NIEHS Sister Study103, identified low birth 
weight (<2,500 grams) to be significantly associated with the odds for lupus (OR 2.2, 
95% CI 1.2-3.9) while another study with the NHS cohort identified high birth weight (≥ 
10 lbs) to be associated with increased risk for lupus (RR 2.7, 95% CI 1.2-5.9) 104. The 
lupus results pose an interesting dilemma. In our prevalent data analysis, there was no 
significant association between lupus and any birthweight category in agreeance with 2 of 
the previous studies 101,102. However, the incident data suggests a positive association 
with between higher birthweights and risk for lupus, agreeing with the NHS study 104. 
When we compare the outcome validation criteria for each study, our WHI study has the 
least stringent criteria.  
Only three studies were identified that examined the association between birth 
weight and MS. Two studies found no association between birth weight and MS, 
including a longitudinal study conducted in Canada and a study performed within the 
NHS 105,106. Within the longitudinal Canadian study, birthweight was assessed as a 
continuous variable, and no association was detected with MS, even after stratification by 
sex (female P=0.48; male P=0.92). The analysis conducted within the NHS analyzed 
birth weight as a categorical variable 106.  An additional case control study from 
Argentina found high birth weight (≥4kg) to increase the odds for MS in men (OR 6.58, 
95%CI 4.81-8.99) and women (OR 4.5, 95% CI 3.06-6.58) 107. However, this study is 
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greatly limited by an unreliable population selection as well as a lack of transparent 
analysis, and therefore, is not internally valid. 
There were two articles examining birthweight, among other early life factors, 
and risk of development of UC/CD 108,109. Both studies found no association between 
birth weight and incident cases of UC or CD. It is worth noting that both studies 
separated CD and UC into separate outcomes, while we were unable to do so due to the 
method of data collection within WHI. However, our results were consistent with these 
two prior studies.    
In contrast to the other autoimmune conditions, a great deal of research has been 
done examining the association between birth weight and T1D. A meta-analysis110 
looking at 29 studies  predominantly within Europe demonstrated that children born at 
both 3.5 - 4 kg (OR 1.06 95% CI 1.01-1.11) and above 4kg (OR 1.10 95% CI 1.04-1.19) 
were at a higher risk for T1D. out of the studies within the meta-analysis none of the 
studies focused on postmenopausal women. This result is further bolstered by several 
other studies conducted more recently 111–113. Our results depart from this previously 
explored relationship; however, our study had much lower power to detect an association, 
highlighted by our small number of cases (n<100) divided across four birth weight 
groups. this could be in large part to do with the population selected by WHI. Women 
collected by WHI must live long enough to become post-menopausal. T1D is known to 
become increasingly crippling as life goes on and might contribute to them being less 
likely to participate in a study such as this one. Additionally, T1D was never reported as 
its own variable within WHI and was collected in tandem with T2D. Due to the lack of 
T1D variable, a set of criteria had to be made that could ascertain T1D from T2D. This is 
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a large departure compared the other studies which used medical records from patient 
registries 112,113, individual patient data 110, and hospital statistics 111. The lack of a 
validated T1D variable could have resulted in improper classification cases and could 
have been another reason that this study demonstrated a null result.   
While the existing literature examining possible links between a person’s weight 
at birth and risk for autoimmune conditions is mostly limited, literature examining the 
impact of birth weight and thyroid conditions is even more scarce. We were able to locate 
one study that considered the association in twin pairs discordant for overt thyroid 
disease and found no associations between birth weight and autoimmune thyroid disease 
(Graves’ and Hashimoto’s thyroiditis) or non-autoimmune thyroid disease (simple goiter 
and toxic nodular goiter) 114. However, we found women born weighing ≥ 10 lbs were at 
significantly increased odds of underactive thyroid and decreased odds for overactive 
thyroid. One possibility for this discrepancy is the use of twins. Twins were one of our 
exclusion criteria due to the presence of competition for resources within the gestational 
environment as well as twins being born at a significantly lower weight then single birth 
115. Another possibility is our substantially larger sample size, which afforded us 
sufficient power to detect the association. The discrepancy in results could be further 
explained by our broad assessment of thyroid conditions that does not specifically assess 
autoimmune thyroid conditions. Finally, the twin control study design of the existing 
study could be susceptible to overmatching, which could bias their results towards the 
null. Other studies have considered the relationship between birth weight and thyroid 




4.2 Strengths & Limitations 
This study has several key strengths. The WHI has a large sample size with 
extensive phenotype data collection at baseline. The prospective design of the WHI also 
allowed us to consider incident cases for four of our outcomes with up to 8 years of 
follow-up data available. We were also able to evaluate a broad spectrum of potential 
confounders that may account for the underlying association between birth weight and 
autoimmune or thyroid conditions. 
Our study also has several limitations. First, our study was limited to evaluating 
categories of birth weight based on the woman’s self-report. While the most ideal birth 
data collection method would have been a quantitative measure obtained through medical 
records or birth certificates, self-reported birth weight by category has been shown to 
correlate well with medical record data in validity studies118,119. Further, any bias that 
might result from potential misclassification of birth weight would be nondifferential.  
Despite the large sample size of WHI, power remained a concern for most of the 
autoimmune outcomes. As stated above, the literature has demonstrated that extremely 
high birth weight is associated with increased risk for several autoimmune conditions. 
However, with <20 individuals within the high birthweight category half of the examined 
conditions, this relationship becomes difficult to detect with statistical significance. This 
lack of power increases the likelihood of a type 2 error or the acceptance of a false null 
hypothesis. The lack of power limited the secondary effect modification that would have 
been useful for conditions like lupus which is known to affect persons of color more than 
those of other races. 
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Birthweight is not the only variable that was collected in a self-reported 
categorical manner. All the outcomes along with some of the covariates were also 
recorded this way. While this has not been demonstrated to be of concern for the 
covariates it is a concern within some of the outcome variables. RA is one such variable 
with questionable validity within WHI. In a 2008 study validating the responses of the 
study in terms of secondary outcomes RA was found to be inaccurate 38. The inaccuracy 
was theorized to result from confusion with osteoarthritis, which has a different etiology 
then RA. To increase the validity of the RA variable, we used medication data collected 
by WHI to validate if the subject was taking drugs indicative of RA 38. The validation 
strategy was easy to implement for the RA baseline analysis but was more intricate when 
working with the incident data. Because medication data was only taken at baseline and 3 
years after enrollment, it was impossible to validate any case that occurred after this 3rd 
follow-up year. Due to this secondary limitation, it was decided that the follow-up of the 
incident RA cases would be artificially terminated at the time of the medication 
collection on the 3rd year of follow-up.  Another variable that was called into question in 
the same WHI validation study was lupus. However, upon analysis of the paper there was 
a much smaller group (total N=42; lupus cases=2)  available for comparison, and the 
validity was indeterminate 38. 
Another limitation of this study is the lack of key covariates associated with these 
conditions. Familial history of these diseases is one such covariate. All the conditions 
have demonstrated that family history of the disease is a strong indicator for the 
development of the condition13,59,67. Another variable that is key for thyroid variables is 
the availability of iodine exposure data. The WHI did not collect information related to 
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iodine levels or consumption within the observational study participants. Iodine 
deficiency has a large effect on thyroid conditions and is the most common cause of 
thyroid conditions in poorer regions of the world 59,65,72,120. However, because iodine 
deficiency is thought to be a minor cause in more developed regions of the world, 
including the US, we would not expect this potential confounder to have much influence 
on our results.  
Lastly the use of prevalent data comes with its own set of challenges and 
limitations. Prevalent data often suffers from causal problems as both exposure and 
outcome measured at the same point in time and therefore are usually hard to establish 
that the exposure predates the outcome, and that the outcome does not predate the 
exposure. For this study in particular this limitation is not of a concern as birth weight is 
one of the earliest exposures available and therefore it is unlikely that outcome 
supersedes our exposure of interest. The limitation of prevalent data is also circumvented 
for select outcomes that were included in the incident analysis. In this instance we have 
separation of exposure data collection and onset of disease and therefore can assume that 
exposure superseded the disease occurrence. 
4.3 Future Directions 
Further research examining the associations between a person’s weight at birth 
and subsequent risk for autoimmune and thyroid conditions is warranted. The existing 
body of literature for all examined conditions (except for T1D) is very limited and 
conflicting. While we were able to add to the body of evidence for many of the 
conditions, our analyses were of limited power for detecting associations, particularly for 
MS, lupus, and RA. In addition, we found significant associations between the highest 
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birth weight category and under- and over-active thyroid, results that now need to be 
replicated in additional populations. Further, we were unable to consider several 
potentially vital confounding variables, including family history of the conditions and 
iodine, nor were we able to consider potential racial disparities in the birth weight and 
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